Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DCAT Week
Not Confirmed
Contact SupplierDCAT Week
Industry Trade Show
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content
NEWS #PharmaBuzz
10 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/senhwa-biosciences-and-beone-medicines-announces-a-clinical-supply-agreement-to-address-the-challenge-of-cold-tumors-302638027.html
07 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251207830814/en/Sonrotoclax-Data-at-ASH-2025-Confirm-Foundational-Potential-Across-B-cell-Malignancies
26 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251126490630/en/U.S.-FDA-Grants-Priority-Review-to-Sonrotoclax-for-the-Treatment-of-Relapsed-or-Refractory-Mantle-Cell-Lymphoma
20 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251120303213/en/BeOne-Medicines-Showcases-Leadership-in-B-cell-Malignancies-at-ASH-2025
17 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251117406992/en/Positive-Phase-3-Results-Support-ZIIHERA-as-HER2-Targeted-Therapy-of-Choice-and-Combination-with-TEVIMBRA-and-Chemotherapy-as-New-Standard-of-Care-in-First-Line-HER2-Positive-Locally-Advanced-or-Metastatic-Gastroesophageal-Adenocarcinoma
06 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251106844872/en/BeOne-Medicines-Announces-Third-Quarter-2025-Financial-Results-and-Business-Updates
Drugs in Development
Details:
The collaboration aims to advance Pidnarulex in the treatment of G4-related disorders.
Lead Product(s): Pidnarulex,Tislelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: Senhwa Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2025
Lead Product(s) : Pidnarulex,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Senhwa Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Senhwa Biosciences, BeOne Medicines Partner for Cold Tumor Clinical Supply
Details : The collaboration aims to advance Pidnarulex in the treatment of G4-related disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 10, 2025
Details:
BG-75098 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): BG-75098,BGB-43395,Fulvestrant
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 10, 2025
Lead Product(s) : BG-75098,BGB-43395,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BG-75098 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 10, 2025
Details:
BG-75202 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): BG-75202,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2025
BG-75202 Alone or Combo in Adults With Advanced Solid Tumors
Details : BG-75202 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2025
Details:
The collaboration aims to advance oncology research through the development of BGB-B2033, an unconjugated antibody targeting GPC3/4-1BB.
Lead Product(s): BGB-B2033,Tislelizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Recipient: InSysBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 29, 2025
Lead Product(s) : BGB-B2033,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : InSysBio
Deal Size : Undisclosed
Deal Type : Collaboration
InSysBio Announces Collaboration with BeOne Medicines
Details : The collaboration aims to advance oncology research through the development of BGB-B2033, an unconjugated antibody targeting GPC3/4-1BB.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 29, 2025
Details:
BG-C0902 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): BG-C0902,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2025
Details : BG-C0902 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 18, 2025
Details:
Zanubrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Waldenstrom Macroglobulinemia.
Lead Product(s): Zanubrutinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2025
Lead Product(s) : Zanubrutinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanubrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Waldenstrom Macroglobulinemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025
Details:
BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Undisclosed Brand Name: BG-71332
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2025
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanubrutinib + Sonrotoclax FDC Tablet Bioavailability & Food Effect In Healthy Adults
Details : BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : BG-71332
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2025
Details:
Under the agrrement, Royalty to acquire rights to BeOne’s royalties on Imdelltra (tarlatamab). It is being indicated for the treatment of of adult patients with extensive stage small cell lung cancer.
Lead Product(s): Tarlatamab,Inapplicable
Therapeutic Area: Oncology Brand Name: Imdelltra
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Royalty Pharma
Deal Size: $950.0 million Upfront Cash: $885.0 million
Deal Type: Agreement August 25, 2025
Lead Product(s) : Tarlatamab,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $950.0 million
Deal Type : Agreement
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Details : Under the agrrement, Royalty to acquire rights to BeOne’s royalties on Imdelltra (tarlatamab). It is being indicated for the treatment of of adult patients with extensive stage small cell lung cancer.
Product Name : Imdelltra
Product Type : Antibody, Unconjugated
Upfront Cash : $885.0 million
August 25, 2025
Details:
BGB-45035 is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Lead Product(s): BGB-45035,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: PROTACs
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2025
Lead Product(s) : BGB-45035,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BGB-45035 Efficacy and Safety In Moderate-Severe Active RA Adults
Details : BGB-45035 is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
August 03, 2025
Details:
Tevimbra (tislelizumab) in combination with gemcitabine and cisplatin, has been approved for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma.
Lead Product(s): Tislelizumab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Brand Name: Tevimbra
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2025
Lead Product(s) : Tislelizumab,Gemcitabine,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves TEVIMBRA + Chemo as 1L Treatment for Nasopharyngeal Carcinoma
Details : Tevimbra (tislelizumab) in combination with gemcitabine and cisplatin, has been approved for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma.
Product Name : Tevimbra
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 10, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
